Category Archives: Growblox Sciences Inc. GBLX

GrowBLOX Sciences, Inc. (GBLX): First of Several Planned Medical Cannabis Cultivation Labs Scheduled for 4Q

September 28, 2015

GrowBLOX Sciences, a biopharmaceutical company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, today reports that the first of its four planned Cultivation Labs – this one a 30,000-square-foot facility in Las Vegas – is scheduled to open by the end of the fourth quarter. In the news release regarding the upcoming opening, the company posted several pictures of its Cultivation Lab (http://finance.yahoo.com/news/growblox-sciences-announces-first-four-130000171.html).

Packed with cutting-edge technology, the Las Vegas Cultivation Lab will feature fully contained clean room structures equipped with state-of-the-art lighting, air handling, humidity control, CO2 management, irrigation and fertigation. A centralized automated system and remote access controls will operate these important features, enabling for a high level of precision environmental control and monitoring essential for the collection of new data that will be invaluable for the medical cannabis industry.

When it comes to production, at full capacity the Las Vegas Cultivation Lab will produce more than 7,000 pounds of certified medical grade raw material annually. It will feature the precision of a laboratory and the size of a greenhouse. As the first of four planned laboratories and at full capacity, the company projects the Las Vegas Cultivation Lab will generate $10 million-$12 million in revenue per annum.

“Our flagship laboratory, the Las Vegas Cultivation Lab, is only the first of four Cultivation Labs being built. As such, it is the standard bearer for the cutting-edge technological growing of medical grade cannabis, and is a timely address to the problem of inadequate supplies of medical grade cannabis. GrowBLOX Sciences continues to be a frontrunner in the medical cannabis industry — and this is only the beginning of great things to come,” chairman of the board and CEO Craig Ellins stated in the news release.

For more information visit www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Acquires 4 Nevada State Medical Cannabis Licenses

September 16, 2015

GrowBLOX Sciences, a biopharmaceutical company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, this morning announced it has acquired four Nevada State Medical Cannabis licenses.

The acquisition of three of the licenses stems from an agreement with Sandra Tiffany, a former state senator of 14 years and an important figure in the legalization of medical cannabis in Nevada, who was recently appointed GBLX’s general manager of Nevada operations.

Craig Ellins, chairman of the board and chief executive officer, stated, “Opportunities, opportunities, opportunities! Through strategic partnerships, and as the acquisition of these licenses demonstrate, GBLX continues its rapid growth in becoming a premier provider of medical cannabis. We are looking forward to a very exciting 2016, as all the hard work we have executed on will transition to commercialization and revenue growth.”

The first license is for a medical cannabis grow license for a location in Pahrump, Nevada. This location comprises a 5,000-square-foot building and 4 acres of open space. This acreage can be used for the construction of an unlimited number of greenhouses growing conventional product. GBLX notes that this acreage would be particularly useful should recreational cannabis also become legal.

The second and third licenses are for a location on 3-1/2 acres in North Las Vegas. These licenses are for both the cultivation and production of medical cannabis. Not only does the cultivation license authorize a grow facility, but the subsequent license authorizes production, allowing GBLX to extract oils from the cannabis flower for vaporization or use in the creation of edibles.

The fourth license is a dispensary license. Although arrangements with certain local Nevada parties were announced, in a subsidiary 55% owned by GBLX (45% by the other Nevada partners), the current arrangement is that GBLX will own 100% of the grow facility, and the Nevada partners will own 90% of the dispensary licenses, only one of which has been granted (by Clark County) on Fort Apache Boulevard. The dispensary application, which is pending with the City of Las Vegas, included in the 90/10 arrangement should be granted. All of these arrangements are subject to certain regulatory approvals.

In addition to its ownership of the dispensaries, GBLX has retained the rights to 20% of the premier shelf space both of the dispensaries for its proprietary cultivation product, as well as the right to completely control and operate the delivery service that was included in the Fort Apache license, on a basis where 80% of the retail price is paid to the company when the company’s proprietary product is delivered. It is expected that only the Company’s proprietary product will be delivered by the dispensary – subject to certain regulatory approvals.

The newly acquired Nevada licenses are in addition to the “TECO” facility, a 30,000-square-foot cultivation lab that will feature cleanroom infrastructure, environmental monitoring and controls, as well as biometric access security. The state-of-the-art design will provide the ideal facilities through with GBLX can produce raw materials at the capacity of a greenhouse with laboratory precision.

For more information, visit www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Leverages Research Partner Discoveries to Fuel Growth

September 15, 2015

The state of Nevada is eager for its upcoming 2016 general election ballot initiative that proposes legalizing recreational use of marijuana. Using Colorado’s $700 million intake last year as a reference point, it sees the state trending to break $1 billion in annual revenues by 2016. With this data, projections from the state Department of Revenue tell us the MMJ market in Nevada could easily get a lot bigger in the months ahead.

GrowBLOX Sciences, Inc. focuses on the research and development of medical cannabis drugs and treatments. Producer of medical-grade cannabis, cannabis concentrates, and cannabinoid therapies through using various technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, the company is involved in the development of controlled-climate indoor agricultural technology growing and cultivation suites.

In the GBLX Drug Development Ecosystem, the company holds the patents and coordinates the research data from all of its research partners. Partner data is pulled together and partners are realize incentives with equity in relative to the value of the data they contribute. Bonus equity can be rewarded retroactively when data previously contributed becomes a part of a patent, IND filing, or NDA filing. The company finds that the equity incentive system increases efficiency and productivity in drug discovery. Further the company encourages real and virtual collaboration among the researchers in the ecosystem.

GB Sciences fills the discovery role in the ecosystem. Other members of the GBLX Drug Development Ecosystem include universities, small and medium biotechnology companies and clinical research organizations (CRO). Preclinical research comes by way of its University partners. Clinical trials are run by Clinical Research Organization (CRO) partners and can be licensed to Pharmaceutical Licensees before the Human Phase III trials. Distribution is through specialty pharmaceutical channels, including hospitals and research centers.

GrowBLOX Sciences combines state-of-the-art technologies in plant biology, cultivation and post-production processes to optimize safe medical Cannabis. The company is pioneering technologies and industry-leading processes in combination with a Big Data-driven clinical research and development program to bring relief to patients all over the United States.

To learn more about the company visit www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

Growblox Sciences, Inc. (GBLX) Bolstering Staff as Subsidiary Prepares to Commence Cultivation Operations

September 1, 2015

Growblox Sciences, Inc. (OTCQB: GBLX) is rapidly approaching the impending commencement of cultivation operations through its majority-owned subsidiary, GB Sciences Nevada, LLC. As a result, the company has turned much of its attention in recent weeks toward transitioning from an engineering intensive development stage to the day-to-day operations related to the production and branding of its innovative products. Among these efforts, Growblox has made significant progress in beefing up its staff to meet the increased demands of production efforts while simultaneously promoting sustainable revenue growth.

In July, the company announced the hiring of John Poss as a consultant. Poss brings more than 15 years of consulting experience to the Growblox team, as well as the knowledge gained from operating as a CEO, COO, CFO and CTO of both public and private firms with sales of up to $450 million. In August, the company built upon this relationship by appointing Poss as its new chief financial officer. Following this announcement, Growblox will look to lean on its newest executive’s considerable industry expertise in order to promote a smooth and expeditious strategic transition.

“First joining us as a consultant, the performance of John Poss and his impact on our company, made the hiring of him as a full-time key executive an obvious choice,” Craig Ellins, chief executive officer of Growblox, stated in a news release. “This choice supports our transition from the engineering intensive development stage to the day-to-day operations of producing an excellent product, branding it appropriately, and maximizing our revenue.”

While it continues to increase the size of its staff, Growblox is currently progressing toward the completion of its new cultivation facility, which will provide a pristine and consistent environment for growing and processing medical cannabis that will also safeguard the company’s proprietary technology and equipment. As of its latest update, Growblox plans to complete construction of the facility before the end of 2015, strategically positioning it to initiate revenue-generating operations as early as next year. In preparation, GB Sciences Nevada has already applied for certification to dispense medical cannabis at two locations in Clark County, Nevada, and it is currently awaiting approval.

With the considerable progress of GB Sciences, as well as the company’s ongoing efforts to finalize the production and testing of its groundbreaking GrowBLOX Suites system in 2016, Growblox is in a favorable position to capitalize on the nation’s thriving cannabis industry in order to promote rapid financial growth in the future.

For more information, visit www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Names John Poss as New CFO

August 25, 2015

GrowBLOX Sciences (OTC: GBLX), a biopharmaceutical company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, today announced John Poss as its new chief financial officer.

“First joining us as a consultant, the performance of John Poss and his impact on our company, made the hiring of him as a full-time key executive an obvious choice. This choice supports our transition from the engineering intensive development stage to the day-to-day operations of producing an excellent product, branding it appropriately, and maximizing our revenue. We feel that John will be instrumental in helping us to achieve that transition smoothly and expeditiously,” stated GrowBLOX Sciences CEO Craig Ellins. “John’s experience, in business and in life, speaks for itself.”

The company describes Poss as having “an aptitude for solving complex problems and improving performance in technology, logistics, business systems, and finance.” Poss previously served as CFO, CEO, COO, and CTO of both public and private companies with sales ranging from $10 million to $450 million as well as over 15 years of consulting experience. He also has extensive M&A experience, both buy and sell side, including private equity. His success has been demonstrated across multiple industries, including telecommunications, transportation/logistics, manufacturing, finance/mortgage, construction, mining, oil, gas, and public accounting/consulting. Additionally, he is a proven innovator with two issued patents. Further, he’s led major projects and negotiated over $1 billion in commercial agreements and dispute resolutions in 15 countries.

“I am very happy to join GrowBLOX. As a cancer survivor, I am a strong believer in the value of medical marijuana in many cases and to treat many diseases. I am excited to be a part of this revolution, which has been developing, slowly, throughout my lifetime,” stated Poss.

For more information visit http://growblox.com.

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

Shifting Gears at GrowBLOX Sciences, Inc. (GBLX)

August 21, 2015

Medical cannabis and cannabinoid-based therapies are gaining wider acceptance around the United States. More than 20 states and the District of Columbia have legalized the drug and, between 2009 and 2014, IBISWorld estimates that the medical cannabis industry grew significantly to reach $2 billion in revenue. Despite this industry boom and the pioneers that emerged within it, there has been a shortage of companies conducting legitimate research and development and/or with the right amount of scientific backing and funding needed to compete in the industry.

GrowBLOX Sciences, a biopharmaceutical research and development company, stands out from the pack with its advanced technologies in plant biology and cultivation. Led by an impressive scientific team that includes big data experts, the company has turned its attention to creating safe, standardized pharmaceutical-grade cannabis-based therapies that target an assortment of medical conditions. The company is focused on bringing relief to patients in communities across the country by combining ground-breaking technology and industry processes with its “big” data-driven clinical research and development loop ability. Moreover, through its Puerto Rico subsidiary, GrowBLOX Sciences is developing and dispensing its suite of cultivation and growing chambers worldwide.

With its novel approach to using big data to produce lower-risk clinical trial candidates, GrowBLOX is highlighting its strong long-term potential. With over 180 cannabis-related human trials registered with the National Institute of Health (NIH) and more on the way, the company has established a brilliant starting point with close to a thousand potential combinations within the cannabinoid-related therapy space.

In the short term, the company intends to earn revenue from selling certified raw materials through dispensaries. These near-term plans were set in May when the company announced the formation of GrowBLOX Sciences Puerto Rico, a subsidiary that will legally grow cannabis raw materials that will be sold solely to its parent company for dispersion in the U.S. and other countries where the drug is legal.

The company’s operations – cultivation, post-processing and manufacturing – create a model platform to execute these visions. On the cultivation side, its TissueBLOX, GrowBLOX and CureBLOX platforms facilitate the efficient growing of cannabis, while its ExtractionLab produces proprietary blends for distribution as pharmaceuticals, nutraceuticals and cosmeceuticals. Given its distinctive business model, long-term potential in pharmaceuticals and short-term potential in raw material sales, GrowBLOX Sciences is a company worth a closer look.

For more information, visit the company’s website at www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Cultivation Technology Promises to Deliver Pure, High-Value Strains at Scalable Production Volumes

August 18, 2015

Medical marijuana continues to act as the narrow end of the wedge for a broader legalization of cannabis and cannabis-derived products nationwide, with parents now demanding medical access across the country to what they see as relatively-safe, life-saving drugs. Such as in the cases like those of two young girls in Pittsburgh (where legislation is currently pending that would allow medical marijuana to be used), ages 12 and 15, reported recently by NBC News. One girl is barely able to move after a nasty series of epileptic seizures and the other was just discharged after a similar episode, consisting of 15 grand mal seizures that occurred within a period of 36 hours.

The mothers of both girls are members of a growing army of parents and national marijuana advocates pushing for legislative reform on the cannabis issue. This efflorescing movement, led by medical access and compassionate care concerns, is being spurred on by the mounting body of empirical evidence emerging from landmark clinical studies which are daily helping to document the benefits of phytocannabinoids, such as CBD (cannabidiol, a non-psychoactive cannabinoid) and THC (the more famous psychoactive cannabinoid), for treating conditions like epilepsy, as well as helping to regulate a wide variety of other problematic conditions, such as chronic pain. In this case, one of the girls is actually enrolled in an ongoing clinical trial, while the other is not. This case shines a bright light on the underlying problem of state legislatures dragging their feet on the issue and offers stark contrast for the recent FDA approval of prescription opioid OxyContin for children as young as 11, who are recovering from extensive trauma or major surgery.

On the other end of the cannabis legalization spectrum from compassionate care and medical access forces we have tax revenues, which are extremely appealing to increasingly strapped state legislatures, and which are looking more and more politically feasible given the growing receptivity to marijuana reform among the general populace. Just recently, ResponsibleOhio, a marijuana reform advocacy group with a $20 million war chest, which is pushing hard for the legalization of at least medical marijuana (MMJ) in Ohio, secured enough signatures to get a ballot initiative on the books for this November. County and local government officials are already starting to buzz about the estimated $554 million in annual tax revenues projected by ResponsibleOhio’s newest report if the state’s legal, regulated cannabis market stabilizes by 2020.

With Washington bringing in $70 million in tax revenues and Colorado pulling down around $40 million during their first years, seven other states are currently poised to pass similar reforms that would at least allow MMJ access for patients. In Nevada, where MMJ was technically legalized back in 2000, dispensaries are just now cropping up after the passage of Senate Bill 374 in 2013, and the subsequent dolling out of operating licenses beginning in late November last year. Clark County, where Las Vegas resides, has been the tip of the spear in many respects, passing its own proactive zoning and land use process regulations for MMJ businesses ahead of schedule. A fact not lost on some analysts, who are projecting a rapid flourishing of the state’s cannabis market. With estimates of around $100 million plus in annual revenues, driven in part by a currently still emerging health tourism-centric regulatory structure, as well as the never-ending influx of people from all over the world who flock to the global entertainment mecca that is Las Vegas every year, Nevada could be one of the fastest growing national markets for cannabis, medical or otherwise.

This seemingly ideal market environment is a major reason why plant biology and cultivation focused biopharma, GrowBLOX Sciences (OTC: GBLX), has targeted Nevada for the rollout of its principal cultivation facility, which will be furnished with the company’s proprietary suite of technologies designed to achieve scalable production of consistently top quality MMJ materials and extracts. With initial production-model units of the company’s GrowBLOX™ controlled-environment solution already shipped to its GB Sciences Nevada (GBSN) and GB Sciences Puerto Rico (GBS PR) facilities, GBLX is fast on its way to demonstrating to the now $3.5 billion U.S. market (2015 estimate according to ArcView), just how far the company has come in terms of designing an efficient lifecycle cultivation solution.

GrowBLOX Sciences is looking to become a major player as the cannabis sector swells to around $10.8 billion over the next four years, deploying its solution – which spans tissue culture propagation of high-value proprietary strains in a controlled environment, through to consistently top quality end product and derived extracts – to eager regions which have passed the requisite reforms. Having secured a $1.75 million funding commitment for the build out of its initial MME (medical marijuana establishment) back in June and having subsequently reported in late July that the company is on track to complete the build of its Nevada Cultivation Labs, GBLX has now reached a major transitional milestone, where the company is focused on branding, production, revenue generation and staffing, instead of R&D, or licensure efforts.

Nevada’s 136 licensed dispensaries, combined with a lack of in-state cultivation, makes this a particularly auspicious move by GBLX, and the company’s state-of-the-art cultivation facility should not only impress sector players by its prowess, it should capture a sizeable share of a state market that is currently estimated as growing by around 341 percent this year alone. Pacific Leaf Ventures ponied up the $1.75 million funding commitment for this initial cultivation lab and has also provided license for IP related to its highly recognizable brand names of cannabis, as well as certain cultivation and extraction techniques. Slated to begin producing sometime in Q4 this year, GLBX’s Nevada Cultivation Labs will not only secure the reputation of the Pacific Leaf brand name and the quality of its cannabis strains through impeccably consistent output (fueling the local market with a scalable supply of products), it will also help cement brand identity and recognition among patients with reciprocal MME cards from neighboring states like Arizona and California.

The incredibly powerful TissueBLOX, GrowBLOX and CureBLOX cultivation architecture developed by GBLX, which allows for scalable production of genetically pure strains of cGMP-certified cannabis, has the potential to transform the cultivation segment of the burgeoning nationwide cannabis space.

Investors are encouraged to learn more about the technology by visiting www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) – Cultivating Turnkey Solutions for the Medical Cannabis Industry

July 31, 2015

GrowBLOX Sciences (“GB Sciences”) is a nature-inspired company employing a novel approach toward cannabis-based medicine. The company is focused on offering a turnkey business solution: transforming cannabis into safe and consistent medicine.

GB Sciences’ focus is on the research of indoor agriculture technology for the medical cannabis industry. The company merges state-of-the-art technologies in plant biology, cultivation and post-production processes in order to optimize safe, consistent medical cannabis. In doing so, the company is also pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm in order to bring relief to patients in communities across the country.

As part of its efforts to lock in industry standards, GB Sciences is developing a comprehensive line of highly effective cannabis-based therapies ranging from custom medical compounds to consumer health and beauty products. GB Sciences’ cultivation methodology ensures a consistent ratio of the plant’s medicinal properties for each and every harvest. This is a critical factor when creating formulations for standardized therapeutic products.

GB Sciences’ drug development program also endeavors to unlock the path to drug discovery and to provide novel cannabinoid therapies to patients with critically unmet needs. The company is developing the GrowBLOX system, a proprietary technology that allows for controlled growing conditions for the manufacture of toxin-free, natural, and medicinal-grade cannabis and cannabis concentrates. Starting with certified, cannabis plant-derived ingredients from the GrowBLOX technology suite, GB Sciences tests proprietary ratios of active ingredients in an accelerated drug development program. It also focuses on the research, testing and development of FDA-approved medical treatments and nutraceuticals using extracts from the cannabis sativa plant.

GrowBLOX Sciences is gearing up to cultivate the medical cannabis industry in new ways. The company’s science and research efforts power discovery, its engineering and design activities bring ideas into the real world, and its big data methodology drives continuous improvement.

For more information, visit the company’s website at www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Initiates Big Changes Ahead of Opening of Nevada Cultivation Facility

July 23, 2015

GrowBLOX Sciences, a biopharmaceutical company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, today announced that over the course of the next few weeks it will implement certain changes in management personnel and operating procedures in preparation for the commencement of cultivation operations through its majority-owned subsidiary, GB Sciences Nevada, LLC.

“The build out of our principal cultivation facility in Nevada is proceeding well and on schedule. As we transition from our engineering intensive development stage, involving largely R&D and licensure efforts, to the day-to-day operations of producing an excellent product, branding it appropriately, and maximizing our revenue, we will need to significantly beef up our staff,” CEO Craig Ellins stated in the news release. “We have brought in John Poss as a consultant to put in effect some of these changes. We feel that John will be instrumental in helping us to achieve that transition smoothly and expeditiously.”

John Poss, a former CPA, is a senior executive with a track record of improving performance in technology, logistics, operations, business systems and finance. His experience includes CEO, COO, CFO and CTO of both public and private companies with sales ranging from $10 million to $450 million as well as over 15 years of consulting experience. He also has extensive M&A experience, both buy and sell side, including private equity. He also holds two United States patents.

The company also plans to appoint a general manager for the GBS Nevada Venture in the near future, as well as support staff for the 30,000-square-foot cultivation facility. Key personnel for the retail location in Las Vegas as well as the delivery service will also be put in place in the upcoming weeks. Product development and scientific validation of consumer facing products will be managed by a combination of in-house scientists and contracted chemists and formulators.

“Our drug discovery strategy and clinical research will be enhanced by the success of our Nevada operations. Profiling proprietary strains for their therapeutic properties is essential for the scientific and medical evolution of cannabis. Our competitive advantage lies in the privilege to legally grow and scientifically study medical cannabis here in Nevada. It is extremely important to our shareholders that we have the ability to test and develop products on a commercial scale but with laboratory precision,” said Chief Science Officer Dr. Andrea Small-Howard.

In conjunction with the aforementioned changes, GBLX has replaced its PCAOB auditor with Patrick Heyn, CPA, who was the concurring auditor for the company’s most recent audited statement. GBLX expects to shortly announce further additions of key personnel to manage the revenue-producing operations expected to begin in the early fourth quarter of 2015.

For more information, visit www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Full-Spectrum Approach to Cannabis Market Rooted in Genetically Pure, High-Grade Strain Cultivation Tech

July 17, 2015

With a legal market size last year of around $2.7 billion, which is projected to expand by a whopping 300 percent over the next four years to around $10.8 billion according to a recent report from ArcView Market Research, the market for cannabis in the U.S. is fueling one of the fastest growing industries the country has to offer. Given that there is yet considerable room for expansion nationwide, as well as positive/widespread consumer sentiment that continues to drive legislative easing of legal restrictions on both medical and recreational use, the industry is primed to blossom nationally, from medical marijuana (MMJ) being legal in just 23 states, D.C. and the territory of Puerto Rico, and recreational use being allowed in Alaska, Colorado, D.C., Oregon and Washington.

The profound benefits of easily tolerable and safe medicines based on established and emerging cannabis science, which have been demonstrated thus far in areas like epilepsy, largely speak for themselves and this vector is an extremely important one for the future of the industry as well, as it will continue to be the narrow end of the wedge for the development of the broader market. This market will eventually contain a rich variety of everything from edibles and extracts by developers like Nutritional High International (OTCQB: SPLIF), to frontline cannabinoid medicines from companies like GW Pharmaceuticals (NASDAQ: GWPH), such as the multiple sclerosis-related spasticity drug Sativex®, or the recently FDA Orphan Drug Designation approved Epidiolex©, designed to treat severe forms of epilepsy.

Another major driver of legislative reform on this issue has of course been tax revenue and with Washington recently noting how it has successfully emulated Colorado’s own achievements in this area, raking in some $250 million in sales over the past year and realizing around $62 million in excise taxes (a figure 72 percent higher than initially forecast), it doesn’t take a rocket scientist to figure out what the future of the cannabis industry here in America will look like. Indeed, it feels like the end of the alcohol prohibition era to many investors and some of the small to mid-cap companies out there today, who are still just cutting their teeth, could be tomorrow’s juggernauts, rivaling some of the top players in the $170 billion plus U.S. alcoholic beverages market, like Anheuser-Busch InBev (NYSE: BUD), Diageo (NYSE: DEO), and Molson Coors (NYSE: TAP).

The key to maturing into such a juggernaut however is a difficult to pull off combination of visionary business modeling, talented personnel, logistical capacity, marketing, understanding of the end-user dynamics, and most importantly the quality of the product itself. This is where an up-and-coming biopharma development company with strong roots in cutting-edge plant biology and cultivation technology like GrowBLOX Sciences (OTC: GBLX) really shines. With an integrated approach to the market, spanning its proprietary grow technology based on tissue sample-based cloning and a controlled environment that yields consistently high-grade product, which is ideal for both consumers and pharma development purposes alike, through to a well-thought-out commercialization and marketing strategy, GBLX is one of the few “pot stocks” around today with a full-spectrum approach to the industry that could emerge as a one of tomorrow’s sector juggernauts.

By leveraging the company’s proprietary TissueBLOX, GrowBLOX, and CureBLOX platforms, GBLX is able to deliver genetically consistent, high-grade strains of certified raw cannabis materials and blends that will not only resonate with consumers in the end markets and fetch premium prices, while simultaneously priming the pump for accelerated human trialing of cannabis-based medicines. Because the company’s lab-based analytical methods allow GBLX to make precise determinations about key strains and the profile of active ingredients in those strains, and because of the company’s tight post-processing via its ExtractionLAB technology, GrowBLOX Sciences is effectively at the forefront of cannabis drug discovery capabilities, due to its ability to target and cultivate the best strains, and to do so in an environment which eliminates almost all of the variables that otherwise represent risk factors that must be compensated for.

Able to reduce the typical 15 to 20 year development window and billion plus required to bring a new drug to market, GBLX’s accelerated drug discovery program harnesses in-house strain science, the ability to cultivate genetically pure and identical plants, as well as the processing technology needed to rapidly establish FDA FastTrack Approvals or Orphan Drug designations. Moreover, the company’s GBLX-PRO app leverages Big Data harvesting techniques in order to create a real-time feedback loop with end-users, allowing for the rapid establishment of highly coordinated strain profile information, cannabis safety profiling, and usage-based symptom relief data. Cannabis-based medicine development targets run the gamut from cancer treatments, cardio protection, compromised immune system products and inflammation fighters, to indications for treating metabolic syndrome, neurological disorders like epilepsy, and more standard fare such as pain management.

The combination of this accelerated drug discovery pipelining solution with the revenue potential from consistently high-grade materials and blends output to the dispensary market is only the beginning of the story for GBLX though, as the company has already shipped out production-model GrowBLOX units to its GB Sciences Nevada and GB Sciences Puerto Rico operations. With a $1.75 million funding commitment established via Pacific Leaf Ventures to get the company’s 4000 pounds per year Nevada-based Cultivation Lab up and running, as well as a clean, highly-efficient brick and mortar dispensary model known as The Apothecary in the works, and an advanced vending machine on the table that easily rivals or surpasses Medbox’s implementation (OTC: MDBX), GrowBLOX Sciences is already well on its way to becoming one of the top integrated operators in the industry.

Tight branding and marketing at the consumer level, combined with high-grade product and an ability to consistently produced scalable quantities for both direct consumption and drug development will be the keys to GBLX’s long-term success.

Learn more by visiting www.growblox.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Prepared to Capitalize on Growth of Medical Cannabis Industry with GrowBLOX Technology Suite

July 6, 2015

In 1996, California became the first state in the country to legalize the use of medical cannabis when it enacted Proposition 215. Less than two decades later, a total of 23 states, as well as the District of Columbia, have legalized marijuana for medicinal purposes, and that progress has come without a single clinical trial taking place. To this point, the medicinal cannabis market has existed without facing many of the regulatory hurdles present in the pharmaceutical industry, but that could be changing soon. With the movement to reclassify cannabis as a schedule II drug at the federal level rapidly gaining steam, the current landscape of the medical cannabis industry could be closing in on a period of transformation.

As a schedule II drug, cannabis could be recognized as a therapeutic treatment with an accepted medical use in the United States, which would dramatically increase the marketability of cannabis-based pharmaceuticals. This shift in perception would likely entice major pharmaceutical players to begin studying the medicinal benefits of marijuana. GrowBLOX Sciences, Inc. (OTCQB: GBLX), through the development and commercialization of its proprietary GrowBLOX technology suite, is prepared to capitalize on this market evolution by providing an unrivalled approach to consistent cannabis production.

The GrowBLOX technology suite was specially engineered to safely and reliably deliver consistent cannabis products by preserving and replicating carefully chosen genetic stock and precisely controlling the growing process. By monitoring everything from lighting conditions and temperature to oxygen and carbon dioxide levels, the company’s innovative products allow for the elimination of many limiting variables in order to maximize the accuracy and consistency of both clinical testing and full-scale production efforts.

In an interview with TNMNews, César Cordero Krüger, chief executive officer of GB Sciences Puerto Rico, provided investors with a detailed look at the vast market potential for GrowBLOX’s groundbreaking cultivation suite as the medical cannabis industry continues to mature. According to Krüger, the epicenter of future medical marijuana production isn’t located in the continental United States, but in the U.S. territory of Puerto Rico.

Puerto Rico’s history as a medical marijuana hub is just beginning. In 2014, Governor Alejandro Garcia Padilla signed an executive order authorizing the manufacturing of medical marijuana across the island. Although details are still under wraps, Krüger highlighted the possibility that the government’s future plans could involve the University of Puerto Rico, giving the local industry access to the university’s molecular science building, cancer research facilities and independent laboratory testing.

With one of the densest concentrations of pharmaceutical industries in the world, Puerto Rico appears to have a major role to play in the future of the medical cannabis industry. Likewise, look for GrowBLOX and its subsidiaries to make waves with the continued development and commercialization of the GrowBLOX technology suite.

For more information, visit www.growblox.com

To listen to the full conversation with César Cordero Krüger, visit www.tnmnews.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Plans to Utilize Three Phase Retail Distribution Solutions to Promote Industry Growth

July 1, 2015

Through the commercialization of its proprietary cannabis cultivation technology, GrowBLOX Sciences, Inc. (OTCQB: GBLX) is building a formidable presence in the burgeoning medicinal cannabis industry. In order to capitalize on this position, the company plans to utilize a specialized three phase retail distribution solution that will allow for comprehensive coverage of the country’s legalized medicinal cannabis markets.

Phase one of GrowBLOX’s projected retail channel solutions is The Apothecary. This unique retail environment combines a simple, clean and clinical design with cutting-edge biometrics and patient verification to ensure a pleasant and safe customer experience. When visiting The Apothecary, patients will have access to highly trained and certified patient-care professionals, who will help determine medical needs and identify therapeutic solutions. Since doctors have limited training in the benefits of cannabinoid therapy products, these professionals are essential to the company’s patient education efforts. For an inside view of The Apothecary, visit https://vimeo.com/129493221.

In order to expand its retail distribution network and bypassing the costs of traditional brick and mortar locations, GrowBLOX Sciences will also offer a collection of Micro-Apothecary self-service vending kiosks, which will serve as phase two of the company’s retail channel solutions. These machines will provide validated patients with a quick and easy way to obtain the company’s products. Since the Micro-Apothecary can be installed in any existing retail location or traditional pharmacy permitted to sell medical cannabis products or distribute clinical trial medication doses. This prudent approach offers GBLX a cost-effective method of exponentially expanding its distribution network in the years to come.

The final phase of the company’s projected retail network is its innovative mobile app. Set to be released in the second half of 2015, this powerful tool will allow patients to generate profiles, track symptoms, browse local inventory options and order products for pickup or delivery through the use of a mobile device. This mobile app will be essential for tracking valuable patient data and streamline distribution efforts beyond the bounds of its physical locations in order to maximize potential growth moving forward.

With a full network of projected retail channel solutions in place, GBLX is in a solid position to promote strong returns in the future. In the coming months, look for the company to continue building upon its recent commercial progress in an effort to maximize market share within the expanding medicinal cannabis industry.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences (GBLX) Seeks Preferred Provider Status in Booming Medical Marijuana Market

June 26, 2015

The State of Nevada is in high anticipation about its upcoming 2016 general election ballot initiative that proposes legalizing recreational use of marijuana. With Colorado’s $700 million wind-fall last year and trending to break $1 billion in annual revenues by 2016, the medical marijuana (MMJ) market in Nevada could very quickly get a whole lot bigger next year.

Poised and positioned to capitalize on this upcoming opportunity is GrowBLOX Sciences (OTC:GBLX). The company has advanced cultivation technology systems that ensure genetic potential of propagated strains that possess more active ingredients per pound than is achieved with any other cultivation method. On June 15, the company secured a $1.75 million funding commitment from Pacific Leaf Ventures to build out its Medical Marijuana Establishment known as The Cultivation Lab through a deal that includes recognizable cannabis brand names and proprietary cultivation and extraction methods. The 28,000-sq.-ft. warehouse is gearing up to produce over 4000 pounds of high-grade cannabis each year.

Although GrowBLOX Sciences deals strictly in medical cannabis products, the monitoring and control systems that are put in place to ensure quality and safety standards at the Las Vegas facility is quickly drawing attention and could possibly be the mandated standard in Nevada by the time legalization is put in place. See The Cultivation Lab design at the following link: http://www.cultivationlabs.com.

GBLX is on schedule for a 4Q completion of The Cultivation Lab. This facility’s purpose is to produce high profile strains and products that appeal to medically approved patients in the state, as well as patients visiting from neighboring Arizona and California. Nevada is the only state to date that recognizes medical marijuana patient cards issued by other states.

The GBLX product line will be distributed from The Apothecary, an eye catching retail space that combines the trustworthy aesthetics of a clean, minimalistic and clinical-feeling interior, with simplified biometrically driven patient verification. The Apothecary layout has a security foyer for initial patient processing, waiting and consultation rooms as well as retail display area, and secure payment section. See the Las Vegas Apothecary at the following link: https://vimeo.com/129493221.

The company believes that combining The Cultivation Labs and The Apothecary will offer patients the quality assurance and safety that they have a grown to expect from any other therapeutic products purchased in the open market. These big moves in Nevada should distinguish GrowBLOX Sciences further from the other players in the field and help make GBLX a preferred solution provider.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Moving to Meet Burgeoning Cannabis Demand via Multi-Channel Distribution Approach

June 22, 2015

With the race now officially on to open the first medical marijuana (MMJ) dispensaries in Nevada, just a month after Nevada Pure broke ground on the state’s first big secure farming operation in east Las Vegas, anticipation is running high across the state regarding the upcoming 2016 general election ballot initiative that may legalize recreational use. Given that Colorado pulled in over $700 million last year and is currently on track to break $1 billion in annual revenues by 2016, according to projections based on state Department of Revenue data, and that a poll back in 2013 already showed 54 percent of Nevadans favored legalization, the MMJ market in Nevada could very quickly get a whole lot bigger next year.

Good news for fast growing biopharma company GrowBLOX Sciences (OTC: GBLX), whose advanced cultivation technology systems ensures maximized genetic potential of selectively propagated strains that ultimately contain more active ingredients per pound than is achieved with other cultivation methods. As of June 15th, the company has secured a $1.75 million funding commitment from Pacific Leaf Ventures to build out its MME (Medical Marijuana Establishment) known as The Cultivation Lab through a deal that includes key, highly recognizable cannabis brand names, as well as proprietary cultivation and extraction methods. This state of the art facility, situated in a 28,000 ft.² warehouse, is set to produce well over 4000 lbs of high-grade cannabis per annum.

With dispensaries cropping up all over the place in Nevada amid a dearth of grow operations, the state faces a supply shortfall, and GBLX is now shrewdly positioned for a mid-Q4 completion of its cultivation facility. This facility’s purpose is to produce high profile strains and products that should appeal directly to MME cardholder patients in the state, as well as in neighboring Arizona and California markets since Nevada is unique to allow medical marijuana patient cards from other states to be recognized.

In addition to the projected medical cannabis market, California currently has a legalization proposal on the ballot for 2016, just like Nevada. Recent consumption demand estimates for California by NORML run in the neighborhood of 2 million pounds per year, a retail market potentially worth as much as around $9 billion at the average cost of $10.00 plus per gram of high quality strains. Even at the average cost per gram of medium quality strains, California represents a potential $6 billion retail market, or half that if we low-ball the cost per gram figure.

The total nationwide cannabis market is around $2.7 billion as of last year according to ArcView Market Research and it grew 70 percent or more between 2013 and 2014. With a 2019 projection of around $10.8 billion, which would be a whopping 300 percent increase, sector operators like GrowBLOX Sciences stand to see considerable upside as things progress further. ArcView’s projections are largely based on an extension of the clear trend of other states following Colorado into the tax revenue generation bonanza, but should not be taken as speculation. Indeed, with multiple states currently moving to either roll back restrictions, or pass measures to open up even recreational use, even as Canada’s Supreme Court handed down a landmark ruling which stipulates that patients can consume their medicine however they want, including in edible or oil form, the future upside for the MMJ sector in North America is tantalizing to say the least.

The company’s initial Nevada location for its retail footprint roll out, branded The Apothecary, with an attractive “compassionate cross ” logo that is easily recognizable by the green cross merged with the heart symbol. Combining the approachable and trustworthy aesthetics of a clean, minimalistic and clinical-feeling interior, with sophisticated, yet simplified biometrically-driven patient verification, The Apothecary layout features a security foyer for initial patient processing, waiting and consultation rooms, as well as a retail display area, and secure payment section. This same model will serve as the template for future retail locations and should help to establish a sense of trust and security among consumers. A clean, safe and above all comfortable experience was the goal in designing The Apothecary, and the company’s initial store will be located just across the street and slightly north of a Walgreens, four miles north of the major medical district in southwest Las Vegas’ Spring Valley area.

By putting together a sophisticated and streamlined, biometrically driven front end to handle registration, consultation and procurement, The Apothecary will be able to deliver a stress-free and quick processing experience to patients, all within an enviably safe environment; something which should set the company apart immediately and make them a preferred solution for consumers.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) Signs Financing, Licensing Agreements for Advancement in Nevada Cannabis Market

June 15, 2015

GrowBLOX Sciences has entered into a Note Purchase Agreement with Pacific Leaf Ventures, LP in which Pacific Leaf has agreed to make an installment loan to GrowBLOX of up to $1.75 million. According to an SEC filing, the financing provides the funding for GrowBLOX subsidiary GB Sciences Nevada, LLC to acquire and install an operating facility, equipment, and other tangible assets for the cultivation of cannabis and the extraction of oils and other constituents present in cannabis, in adherence to Nevada legal requirements.

GBS Nevada holds a provisional certificate from the Division of Public & Behavioral Health of the Nevada Department of Health and Human Services to operate an establishment to cultivate medical cannabis in Clark County Nevada. The certificate is considered provisional until the establishment is in compliance with applicable local government requirements and has received a state business operating license.

In a related development, GrowBLOX also entered into an exclusive perpetual license agreement to make use of Pacific Leaf’s intellectual property (IP) for the cultivation of cannabis and extraction of oils and other strains of cannabis that it has developed or acquired for the sole use of GBS Nevada in its operations within the state of Nevada. In consideration for the license, GrowBLOX has agreed to pay Pacific Leaf a 14 percent royalty for a period of five years, and a 7 percent royalty each year for five years thereafter.

As part of the Pacific Leaf license, GrowBLOX was also granted the exclusive perpetual right in Nevada to use certain proprietary techniques developed by Pacific Leaf for the extraction of oils from the product grown in the Nevada facility, using the extraction equipment financed by the proceeds of the Pacific Leaf loan. In connection therewith, GrowBLOX agreed to pay a royalty of $2 per extracted gram for a period of five years.

GrowBLOX said it believes that the rights to Pacific Leaf’s IP will give GBS Nevada a “significant competitive advantage in the Nevada cannabis market.” This advantage is complementary to GrowBLOX’s broader business strategy to integrate state-of-the-art technologies in plant biology, cultivation, and post-production processes to optimize safe, consistent medical cannabis.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

A Full-Spectrum Approach to the Medical Cannabis Industry is grounded in Data-Driven Cultivation & Drug Development

June 8, 2015

With news in just last week that the Republican-controlled House of the Texas Legislature has approved cannabis oil for medicinal purposes, as the passage of Senate Bill 339, known as the “Texas Compassionate Use Act,” means Governor Greg Abbott is now within striking distance of allowing dispensing organizations to obtain a license to dispense low-THC cannabis in the state, the medical marijuana industry is once again buzzing about the upper limit potential of this sector. Passage of SB 339 would make Texas the latest addition to a growing list of states in the U.S. passing similar landmark medical marijuana (MMJ) legislation, spurred on by mounting scientific evidence for cannabis-based therapies being able treat the clinically unmet needs of numerous types of patients, particularly in cases of intractable epilepsy, where conventional antiepileptic drugs have failed.

The Texas bill’s passage could be big news for a market that was already estimated to be running around $2.7 billion last year here in the U.S., according to data from cannabis industry investment and research firm, ArcView Market Research. ArcView calculated a 74% jump last year over 2013’s figures for what is, according to their broader analysis, now the fastest growing industry in the entire country. Projections for this year are in the neighborhood of $3.5 billion, a figure expected by ArcView to rise a whopping 208% or more by 2019, as more and more states pass not only similar compassionate care laws decriminalizing some form or other of medical cannabis, but perhaps even going for blanket legalization like in Colorado, which raked in some $53 million in tax revenues during their first year of legalization.

One of the more exciting companies in this fast-growing sector is GrowBLOX Sciences (OTCQB: GBLX), which has developed a host of key technologies needed to thrive in this yet-nascent industry. GrowBLOX Sciences has organized itself into three distinct divisions in order to pursue the company’s bold operational goal set, which spans big data-driven clinical R&D, as well as cultivation using their proprietary GrowBLOX™ Technology suite of systems.
The company has even organized a commercial product development division for targeting dispensaries and various other end markets. You can take a look at the company’s website by visiting www.growblox.com

The company’s GB Sciences division, which focuses on scientific validation and new drug discovery, plans to use certified raw materials matured in the GrowBLOX™ cultivation chambers to develop novel cannabis-based therapies. Leveraging a data-driven biopharmaceutical development approach of running therapies through accelerated human phase IV clinical trials is visionary. This “fast-track” process will be supplemented and accelerated by the company’s proprietary Patient-Reported Outcomes (PRO) smartphone app, which will also enhances the company’s ability to test and refine the chemical ratios of active ingredients. Investors should watch GBLX closely. The long-term patient data that the company will be aggregating via their patient-reported outcomes based smartphone app will also help improve the company’s predictive treatment algorithm approach to therapy development. Harnessing this data is one of the key advantages the company will have in the long run, something that will give GBLX a significant edge over competitors.

The current players in the medical cannabis space are just now scratching the surface of the opportunities that are manifesting at every turn when applying a comprehensive scientific approach to this booming cannabis market.

Investors will want to keep a close eye on companies like GrowBLOX Sciences. As the industry evolves into more than just cultivating a plant, it will be the new technologies, as well as the data that emerges from this, that will be of enormous value just around the corner.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

A Full-Spectrum Approach to the Medical Cannabis Industry is Grounded in Data-Driven Cultivation & Drug Development

June 1, 2015

With news in just last week that the Republican-controlled House of the Texas Legislature has approved cannabis oil for medicinal purposes, as the passage of Senate Bill 339, known as the “Texas Compassionate Use Act,” means Governor Greg Abbott is now within striking distance of allowing dispensing organizations to obtain a license to dispense low-THC cannabis in the state, the medical marijuana industry is once again buzzing about the upper limit potential of this sector. Passage of SB 339 would make Texas the latest addition to a growing list of states in the U.S. passing similar landmark medical marijuana (MMJ) legislation, spurred on by mounting scientific evidence for cannabis-based therapies being able treat the clinically unmet needs of numerous types of patients, particularly in cases of intractable epilepsy, where conventional antiepileptic drugs have failed.

The Texas bill’s passage could be big news for a market that was already estimated to be running around $2.7 billion last year here in the U.S., according to data from cannabis industry investment and research firm, ArcView Market Research. ArcView calculated a 74% jump last year over 2013’s figures for what is, according to their broader analysis, now the fastest growing industry in the entire country. Projections for this year are in the neighborhood of $3.5 billion, a figure expected by ArcView to rise a whopping 208% or more by 2019, as more and more states pass not only similar compassionate care laws decriminalizing some form or other of medical cannabis, but perhaps even going for blanket legalization like in Colorado, which raked in some $53 million in tax revenues during their first year of legalization.

One of the more exciting companies in this fast-growing sector is GrowBLOX Sciences (OTCQB: GBLX), which has developed a host of key technologies needed to thrive in this yet-nascent industry. GrowBLOX Sciences has organized itself into three distinct divisions in order to pursue the company’s bold operational goal set, which spans big data-driven clinical R&D, as well as cultivation using their proprietary GrowBLOX™ Technology suite of systems. The company has even organized a commercial product development division for targeting dispensaries and various other end markets. You can take a look at the company’s website by visiting www.growblox.com.

The company’s GB Sciences division, which focuses on scientific validation and new drug discovery, plans to use certified raw materials matured in the GrowBLOX™ cultivation chambers to develop novel cannabis-based therapies. Leveraging a data-driven biopharmaceutical development approach of running therapies through accelerated human phase IV clinical trials is visionary. This “fast-track” process will be supplemented and accelerated by the company’s proprietary Patient-Reported Outcomes (PRO) smartphone app, which will also enhances the company’s ability to test and refine the chemical ratios of active ingredients. Investors should watch GBLX closely. The long-term patient data that the company will be aggregating via their patient-reported outcomes based smartphone app will also help improve the company’s predictive treatment algorithm approach to therapy development. Harnessing this data is one of the key advantages the company will have in the long run, something that will give GBLX a significant edge over competitors.

The current players in the medical cannabis space are just now scratching the surface of the opportunities that are manifesting at every turn when applying a comprehensive scientific approach to this booming cannabis market.

Investors will want to keep a close eye on companies like GrowBLOX Sciences. As the industry evolves into more than just cultivating a plant, it will be the new technologies, as well as the data that emerges from this, that will be of enormous value just around the corner.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

GROWBlox Sciences, Inc.’s (GBLX) Advantageous Approach to Medical Cannabis Highlighted at CannabisFN

May 26, 2015

CannabisFN this morning highlighted GROWBlox Sciences’ role in the cannabis and pharmaceutical industries, paying particular attention to the company’s “unique business model, long-term potential in pharmaceuticals, and short-term potential in raw material sales.”

Read the full report here: http://www.marketwatch.com/story/growblox-sciences-takes-integrated-approach-to-cannabis-medicine-2015-05-25?page=1

Twenty three U.S. states and the District of Columbia have legalized marijuana, and according to IBISWorld estimates, broader acceptance of cannabinoid-based therapies throughout the U.S. has spurred the medical cannabis industry’s CAGR of 16.2% to reach $2 billion in revenue between 2009 and 2014.

As CannabisFN points out, GROWBlox Sciences stands out from numerous would-be competitors in the industry with its cutting-edge plant biology and cultivation technologies and scientific team comprised of professionals in multiple areas of relevant medicine:

• Chief Science Officer Dr. Andrea Small-Howard
• Big data expert Dr. Long Nguyen
• Botanical expert Dr. Ulrich Reimann-Philipp
• Immunologist expert Dr. Helen Turner
• Small molecule expert Dr. Tony Ortiz
• Clinical investigator expert Dr. Daniel Chueh
• Orthopedic expert Dr. Alfredo L. Axtmayer
• Liver disease expert Dr. John Abroon

Whereas many companies in the cannabis industry administer generic forms of THC or CBD in an attempt to elicit a desired response, says CannabisFN, GROWBlox’s approach is to correlate the profiles of active ingredients within cannabis, including cannabinoids and terpenes, with the symptom and disease-specific improvements in patient outcomes – putting the company at high valuation potential when it comes to market application and opportunity.

The report notes:

“Based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, the company has identified the most effective cannabinoid and terpene profiles for the treatment of conditions within seven therapeutic categories, including cancer treatments, cardio protection, metabolic syndrome, pain management, neurological disorders, and inflammation.

“These categories represent hundreds of billions of dollars in potential value, with markets like the neurological disorder market alone accounting for $952 billion in value. By taking a targeted approach that leverages research already done, the company’s strategy could dramatically improve the odds of success, whilst cutting down on the costs associated with hit-or-miss early stage testing.”

CannabisFN also highlights several other differentiating advantages, including an accelerated drug development and regulatory strategy.

GROWBlox’s proprietary drug discovery program enables drug development within three to five years instead of the traditional 15 to 20 years. This strategy also significantly reduces development costs – which typically sit around $1 billion for “big pharma” pharmaceutical commercialization – to less than $10 million.

Using its proprietary smartphone app as a drug discovery engine, GROWBlox correlates strain profile information with symptom relief and then leverages the existing cannabis safety profiles, fast-track approvals, and orphan drug designations, of research partners, which are incentivized with equity in proportion to the value of data contributed that becomes part of a patent, IND filing, or NDA filing with regulatory bodies.

“In essence, the company is focused on the initial discovery of promising compounds, while universities handle pre-clinical trials, CROs handle clinical trials, and pharmaceutical partners handle distribution. The discovery phase provides the greatest return on capital and diversification relative to other areas of the development process that are much more capital intensive,” the report states.

CannabisFN wraps up the report by highlighting GROWBlox’s end-to-end operations and technologies, the company’s long-term and short-term potential, and broader peer comparison.

“GROWBlox Sciences has clear long-term potential with its innovative approach that leverages big data to produce lower-risk clinical trial candidates. With 188 human cannabis trials registered with the National Institute of Health and more on the way, the company has an excellent starting point of about a thousand potential combinations within the cannabinoid-related therapy space.

“In the nearer-term, the company plans on earning revenue from the sale of certified raw materials through dispensaries. These plans were solidified in May when it announced the formation of Growblox Sciences Puerto Rico LLC, which will legally grow cannabis raw materials that will be exclusively sold to GROWBlox Sciences for distribution in the U.S. and other countries where it’s legal …

“The nutraceutical and cosmeceutical formulations could also be sold in stores without approvals, since the CBDs are sourced from low-THC hemp plants. In some ways, the company could then compete with the likes of GNC Holdings Inc., or Nutraceutical International Corp. in the provision of legal over-the-counter supplements designed to support health.”

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

Growblox Sciences, Inc. (GBLX) Prepares for Commercialization through Launch of New Subsidiary

May 15, 2015

Growblox Sciences earlier this week took a step toward the commercialization of its GrowBLOX™ technology suite through the establishment of Growblox Sciences Puerto Rico, LLC (GBS PR), a majority-owned subsidiary housed on the Caribbean commonwealth. The move comes on the heels of an executive order issued last Sunday by Governor Alejandro Garcia Padilla authorizing the use of some or all controlled substances or derivatives of the cannabis plant for medical use. Through a collaboration with GrowBlox the island is now launching a clinical investigation into the use and production of medicinal cannabis.

“We are very excited by the timing of this announcement as it coincides with our continuing presence in Puerto Rico and our commitment to realizing significant fundamental growth this fiscal year,” Craig Ellins, CEO and chairman of Growblox, stated in the news release.

GBS PR immediately entered into a commercialization agreement with its parent company designed to accelerate the production and marketing of the company’s proprietary cultivation suite. Under this agreement, GBS PR was granted exclusive worldwide rights to produce, lease and license the GrowBLOX™ technology suite, including additional revenue streams for financing costs, training fees and maintenance services. As for the product, the agreement stipulates that GBS PR will sell cGMP-certified raw cannabis and hemp materials exclusively to its parent company for international resale or manufacturing processes.

Indications are promising that Growblox is ramping up its production efforts at the perfect time. According to a study by Pew Research Center, support for marijuana legalization is rapidly outpacing opposition, with a slim majority responding in favor of outright legalization in a 2015 survey. This public support is most clearly identifiable by studying the recent actions of state legislatures. Currently, nearly half of all states allow for the use of medicinal cannabis, and four states and the District of Columbia have passed measures to legalize marijuana use outright.

In an effort to streamline the launch of its new subsidiary, Growblox has appointed Cesar Cordero-Kruger, veteran entrepreneur and local philanthropist, as CEO of GBS PR. In addition to providing the first installment of financing required to launch the new company, Cordero-Kruger also purchased 2,820,000 shares of GBLX common stock. It is expected that the remaining funding required to launch the new subsidiary will be secured from investors on the island without any further cash investment by Growblox.

Under the management of Cordero-Kruger, GBS PR gains significant access to potential projects with the University of Puerto Rico. The new CEO formerly served as a professor of Statistics and Operations Management at the Rio Piedras Campus. As the island territory’s Health Secretary begins to form a report on how to implement the governor’s executive order, the new company’s ties to the island’s premier educational institution could give it a strategic advantage moving forward.

“For almost the past year Growblox has been exploring initiatives in Puerto Rico including potential projects with the University of Puerto Rico,” stated Ellins. “We are pleased to announce the leadership and support of a recognized figure such as Cesar.”

With an inside track on a new potential market, as well as continued advancement toward the commercialization of its product suite, Growblox is in a strong position to realize considerable growth in the coming months. Look for the company to continue establishing its presence in the medicinal cannabis industry for the foreseeable future.

For more information, visit www.gbsciences.com

Let us hear your thoughts: Growblox Sciences, Inc. Message Board

GrowBLOX Sciences, Inc. (GBLX) is “One to Watch”

May 14, 2015

GrowBLOX Sciences, a biopharmaceutical research and development company, is focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies for various medical conditions. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

The company’s GrowBLOX technology suite includes the TissueBLOX, GrowBLOX, and CureBLOX equipment. Together, these components provide unparalleled control and monitoring of cannabis cultivation throughout the plant’s life-cycle. These patent pending processes were designed to produce a safe and consistent cannabis product under cGMP guidelines. Utilizing a computer-regulated system that optimizes the nutrients, water, temperature, and gas levels, the GrowBLOX suite produces cannabis with more active ingredients per pound than traditional cultivation methods.

Also, based on an analysis of preclinical and clinical data from thousands of peer-reviewed studies, GrowBLOX Sciences has identified the most effective profiles of cannabinoids and terpenes for the treatment of conditions within seven therapeutic categories. As a result of this extensive research and the analysis of the active ingredient profiles of 30,000 Cannabis strains in conjunction with a major testing lab, the company will be able to provide patients with natural cannabis strains containing the ideal ratios for treating specific diseases or symptoms.

Another significant advantage held by the company stems from an accelerated drug development program to finish in 3-5 years instead of the 15-20 years typically seen in traditional pharmaceutical development programs. Armed with an intellectual property strategy that takes full advantage of the design of the GrowBLOX technology suite and protects the valuable foundation laid, GrowBLOX Sciences has positioned itself well for long-term success in the burgeoning cannabis space.

For more information, visit www.growblox.com

Let us hear your thoughts: Growblox Sciences, Inc. Message Board

Growblox Sciences (GBLX) Announces Commercialization Initiative and Financing

May 13, 2015

Growblox Sciences, a biopharmaceutical research and development company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, announced today it has established Growblox Sciences Puerto Rico, LLC (“GBS PR”), a majority-owned subsidiary domiciled in Puerto Rico.

“As widely reported, Puerto Rico Governor Alejandro Garcia Padilla recently signed an executive order authorizing the production of medical cannabis. We are very excited by the timing of this announcement as it coincides with our continuing presence in Puerto Rico and our commitment to realizing significant fundamental growth this fiscal year.” Stated Growblox Sciences’ CEO & Chairman Craig Ellins.

In connection with its formation, GBS PR entered into a commercialization agreement with Growblox designed to accelerate the production and marketing of the Company’s proprietary cultivation suite. Growblox believes that the growing chambers and related equipment will facilitate the global manufacturing and distribution of cannabis and other plant-based medical solutions to combat a variety of clinically diagnosed health issues.

Under the commercialization agreement, GB Sciences Puerto Rico, LLC has been granted the exclusive world-wide rights to produce, lease and license the GrowBLOXTM technology suite, as well as the potential for other multiple revenue streams, including the financing of GrowBLOXTM technology suite units; fees for training and maintenance services, and diagnostic monitoring services during cultivation. Additionally, the agreement contemplates that GBS PR will sell cGMP-certified raw cannabis and hemp materials only to Growblox for international resale or manufacturing of cosmeceutical, nutraceutical, and pharmaceutical products.

Cesar Cordero-Kruger, veteran entrepreneur and local philanthropist, has been appointed CEO of the subsidiary. Mr. Cordero-Kruger has provided the first installment of the financing required to launch GBS PR operations from its new office in the capital of Puerto Rico, San Juan. Mr. Cordero-Kruger will own a minimum of 13% of the equity of Growblox Sciences Puerto Rico. It is intended by both Growblox and Mr. Cordero-Kruger that a minimum of $1,250,000 of funding for GBS PR will be provided by local sources on the island without any further requirement of cash investment by GBLX.

Mr. Cordero-Kruger has over 30 years of management experience in a diverse spectrum of businesses and academic environments. Since 1995 he has been a consultant for a major national drugstore chain, assisting with their expansion plans in Puerto Rico and the US Virgin Islands, resulting in the successful launch of over 60 new stores valuing approximately $500 Million in total development costs. He is a co-founder of General Management Assistant Corp. and was engaged by the Commonwealth of Puerto Rico’s Economic Development Administration on a variety of projects such as a feasibility analysis for the air cargo transportation industry, pilot’s school and air ambulance services in the Caribbean. Mr. Cordero-Kruger served as a professor of Statistics and Operations Management at the College of Business Administration of the Rio Piedras Campus, University of Puerto Rico, and was a system design, work measurement, and quality control professor at the Industrial Engineering department of the Polytechnic University of Puerto Rico.

Growblox Sciences, Inc. (GBLX) Updates Communication Strategy with Launch of New Corporate Website

May 12, 2015

Growblox Sciences, a biopharmaceutical research and development company focused on the production of consistent medicinal cannabis, announced on Monday the launch of its new corporate website.

“We have navigated many obstacles in the process of refining our vision and gathering a complete understanding of the medicinal cannabis landscape,” stated Craig Ellins, the company’s Chief Executive Officer. “Growblox is here to cultivate an industry, not just a plant.”

The medicinal cannabis industry is continuing to expand, particularly in the United States. In addition to four states and Washington D.C. moving to legalize recreational use of cannabis in recent months, 19 states currently have laws on the books that allow for medicinal use of the plant. As public support for marijuana continues to rise, climbing to 55 percent in 2014, according to a survey by CNN, additional channels for scientific inquiry should allow the industry to flourish, particularly from a medicinal perspective.

With a focus on science and research, Growblox is in a strong position to grow with the industry. The company’s new website provides potential investors with an extensive supply of content regarding Growblox’s operating divisions: GB Sciences, GB Solutions and GB Products.

GB Sciences, led by the company’s Chief Science Officer, Dr. Andrea Small-Howard, is responsible for regulatory, compliance, clinical trials, product claim validation and new drug discovery. GB Solutions focuses on logistical details of the company under the leadership of Puerto Rican business leader Cesar Cordero-Kruger. GB Products, which is currently scheduled for launch by the end of Q3 2015, will handle product design and marketing efforts under the leadership of Growblox Co-founder Lucas Marin.

Through the launch of its new corporate site, Growblox is initializing a new communication strategy designed to target potential partners and investors. This plan should allow the company to continue to increase market share in the fast growing medical cannabis space. By merging state-of-the-art technologies in plant biology, cultivation and post-production processes, the company is pioneering industry-leading processes to produce safe, consistent medical cannabis. With the increasing demands of the industry, Growblox should be in a strong position to make significant strides moving forward.

For more information, visit www.gbsciences.com

Growblox Sciences (GBLX) Announces Launch of New Corporate Website

May 11, 2015

Growblox Sciences, a biopharmaceutical research and development company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, announced today the launch of its new corporate website.

“We have navigated many obstacles in the process of refining our vision and gathering a complete understanding of the medicinal cannabis landscape. We believe that our evolution has enabled a compelling message to emerge very clearly, which we are pleased to present on our new corporate site; Growblox is here to cultivate an industry, not just a plant,” said CEO Craig Ellins.

The corporate site http://www.Growblox.com provides extensive content regarding the Company’s position in the market and is intended to highlight three (3) operating divisions of the Company: GB Sciences, GB Solutions and GB Products.

– GB Sciences: Handles all regulatory, compliance, clinical trials, product claim validation and new drug discovery. Led by Growblox Sciences’ Chief Science Officer, Dr. Andrea Small-Howard, this division is expected to collaborate with academic and institutional partners, such as the University of Puerto Rico and various clinical research organizations, in order to create a novel cannabinoid therapy pipeline.

– GB Solutions: Focuses on supply chain and logistics and will be overseen by Puerto Rican business leader Cesar Cordero-Kruger, as head of our majority owned subsidiary Growblox Sciences Puerto Rico, LLC. Under his leadership the GB Solutions division will be responsible for all engineering, industrial design and systems validation including the commercialization of company’s propriety cultivation system known as the GrowBLOX(TM) Technology Suite.

– GB Products: Expected to be formally launched by the end of Q3 2015. Lead by Growblox Sciences’ Co-founder Lucas Marin, this division will be taking over product design, marketing and distribution of consumer ready cannabinoid therapies and specialized products.

The website also features the Company’s focus on scientific validation for the medical cannabis industry, supply chain solutions designed to set a path for national distribution and the strong brand identities that will lead the future of cannabinoid therapies. This is the first step of the new communication strategy that the biotechnology company will deploy to target potential partners and investors in the fast growing medical cannabis space.

Growblox (GBLX) Signs License Agreement Including Initial Royalty Payment of $300,000 on its New Technology for the Consistent Production of Medical Cannabis

February 4, 2015

GrowBLOX Sciences, Inc., a biopharmaceutical research and development company with state-of-the-art technologies in plant biology and cultivation, which are designed to produce consistent medicinal cannabis, has signed an agreement to license certain of its proprietary TissueBLOX technology to an unaffiliated licensed cannabis testing company. The licensed technology consists of certain equipment, procedures, and know-how related to the seedless propagation of genetically-identified strains of cannabis. The technology will enable the licensee to offer as a service to third-party growers the ability to grow specific strains of cannabis with an unprecedented level of reliability, precision, and most importantly, consistency of genetic material. As a practical matter what this means is that any grower, having developed and tested a strain of cannabis with certain characteristics desired by the grower, can provide for the continuous and consistent production of the genetics for that strain, enabling it to be branded as either a recreational or medicinal product.

The TissueBLOX technology enables propagation of genetically consistent strains by means of growth from direct tissue cultures, as opposed to cloning or the planting of seeds. Dr. Ulrich Reimann-Philipp, Botanist and Cultivation Manager at GB Sciences said, “We have tissue culture technology that enables scalable production of cannabis strains with a genetic consistency not available by any other means. Cultivators who seek to brand a product, regardless of the characteristics or intended purposes of that product, can now genetically identify, isolate, and reproduce that strain efficiently and cost-effectively. We believe that this branding is a natural progression in the development of the newly emerging cannabis business, and will enable consumers to better select whatever it is they may seek from the product.” Dr. Reimann-Philipp continued, “Of course, in order to provide consistency, growing conditions need to be standardized and strictly controlled as well. Our TissueBLOX system optimizes the ‘nature’ part of the equation, but growers will still need to provide consistency in the equally important ‘nurture’ part of the process.”

The agreement provides for nonrefundable advance royalty payments, which have been received in the last 60 days, against a continued stream of revenue resulting from the sale of the service by the licensee to third parties. Management believes that, in addition to the other revenue streams available to it from its growing activities and the development of its own proprietary strains, the ability to license its substantial suite of proprietary technologies will produce ongoing revenue as a separate business line for many years to come, and will help to take a fledgling industry to a more mature, and thus consumer friendly, place.

Archives

Select A Month
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search

    Categories

    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • 92 Resources Corp. RGDCF (6)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABcann Global Corp. ABCCF (14)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (33)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • Algae Dynamics Corp. ADYNF (28)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • Alltemp, Inc. LTMP (1)
  • AlphaTrade.com APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (47)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • AppSwarm, Inc. SWRM (17)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (29)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • Barchart.com (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • BizRocket.com Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Moon Zinc Corp. BMOOF (3)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • Bollente Companies, Inc. BOLC (7)
  • BoonMarket.com (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cache Elite Inc. ILUS (2)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises, Inc. CDII (48)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (36)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  • Chineseinvestors.com, Inc. CIIX (65)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • Connect-A-Jet.com CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (160)
  • ContentChecked Holdings Inc. CNCK (60)
  • Continental Fuels Inc. CFUL (2)
  • Converde Energy USA Inc. XFUL (12)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (73)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecosciences Inc. ECEZ (1)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • EFoodSafety.com Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (8)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz, Inc. EPAZ (28)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Etelcharge.com Inc. ETLC (3)
  • Ethema Health Corporation GRST (7)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • EVIO, Inc. EVIO (5)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • eXp World Holdings, Inc. EXPI (81)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (11)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  • Fund.com, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • GainClients Inc. GCLT (9)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (90)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Payout Inc. GOHE (51)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • GotStocks.net (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • Greenkraft, Inc. GKIT (9)
  • Greenstone Holdings Inc. GSHN (2)
  • GREM USA GRMU (2)
  • Grey Cloak Tech, Inc. GRCK (5)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (49)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Halitron Inc. HAON (11)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HighCom Global Security Inc. HCGS (13)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IFAN Financial Inc. IFAN (34)
  • iGambit, Inc. IGMB (5)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Immune Therapeutics Inc. IMUN (11)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital, Inc. IGC (21)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • InMed Pharmaceuticals, Inc. IMLFF (32)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (226)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (9)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kootenay Zinc Corp. KTNNF (12)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Laguna Blends Inc. LAGBF (53)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lexaria Bioscience Corp. LXRP (29)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (18)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Loans4Less.com Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • LottoGopher Holdings Inc. LTTGF (10)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Marijuana Company of America, Inc. MCOA (4)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medical Innovation Holdings, Inc. MIHI (4)
  • Medical Transcription Billing Corp. MTBC (13)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • MGX Minerals, Inc. MGXMF (6)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Momentous Entertainment Group Inc. MMEG (19)
  • Monaker Group Inc. MKGI (48)
  • Money4Gold Holdings Inc. MFGD (3)
  • MortgageBrokers.com Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (62)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • MyStaru.com Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • National Waste Management Holdings Inc. NWMH (24)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • Net Element Inc. NETE (19)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (21)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (63)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One Step Vending Corp. KOSK (2)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,353)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • ORHub, Inc. ORHB (25)
  • OTCPicks.com (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (78)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot One Technologies, Inc. PTOTF (19)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • PetroSun Inc. PSUD (41)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Players Network PNTV (15)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • PotNetwork Holding, Inc. POTN (15)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProBility Media Corp. PBYA (33)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (551)
  • QualityStocks Stock Newsletters (18,172)
  • QualityStocks Video Charts (286)
  • QualityStocks.net Market Basics (6)
  • QualityStocksNewsBreaks (216)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • RJD Green Inc. RJDG (3)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (109)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Skinny Nutritional Corp. SKNY (19)
  • Skinvisible, Inc. SKVI (3)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • Smallcaps.us (22)
  • SmallCapVoice (428)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (37)
  • Start Scientific Inc. STSC (22)
  • Stealth Technologies, Inc. STTH (3)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,920)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune, Inc. TPIV (15)
  • Tapinator, Inc. TAPM (3)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (68)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Green Organic Dutchman Holdings Ltd. TGOD (3)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (36)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.